Thursday, June 08, 2017 8:24:17 AM
VSTM - 2.12 Pre-market at 2.43/2.44
Verastem Study of Duvelisib in Non-Hodgkin Lymphoma Meets Primary Endpoint; Shares Rally 11%
Verastem Study of Duvelisib in Non-Hodgkin Lymphoma Meets Primary Endpoint; Shares Rally 11%
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
